Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Citizens Business Bank

Citizens Business Bank increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,125 shares of the biopharmaceutical company’s stock after buying an additional 114 shares during the quarter. Citizens Business Bank’s holdings in Regeneron Pharmaceuticals were worth $3,216,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of REGN. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management raised its position in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. Finally, Colonial Trust Advisors acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 1.6%

NASDAQ:REGN opened at $578.05 on Friday. The business’s fifty day moving average price is $574.64 and its 200 day moving average price is $562.89. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,002.69. The firm has a market capitalization of $61.27 billion, a price-to-earnings ratio of 14.57, a PEG ratio of 1.77 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the previous year, the company posted $11.56 earnings per share. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on REGN. Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. UBS Group reaffirmed a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Finally, Sanford C. Bernstein upped their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $817.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.